Mangalam Drugs and Organics Ltd
Incorporated in 1977, Mangalam Drugs
& Organics Ltd manufactures Active Pharmaceutical Ingredients and
Intermediates[1]
- Market Cap ₹ 45.0 Cr.
- Current Price ₹ 28.4
- High / Low ₹ 95.0 / 22.7
- Stock P/E
- Book Value ₹ 80.6
- Dividend Yield 0.00 %
- ROCE 8.05 %
- ROE 4.68 %
- Face Value ₹ 10.0
Pros
- Stock is trading at 0.35 times its book value
Cons
- Company has low interest coverage ratio.
- Promoter holding has decreased over last quarter: -14.6%
- Promoter holding is low: 35.6%
- Contingent liabilities of Rs.34.6 Cr.
- Debtor days have increased from 36.2 to 44.8 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|
| 369 | 318 | 238 | |
| 351 | 282 | 237 | |
| Operating Profit | 17 | 36 | 1 |
| OPM % | 5% | 11% | 1% |
| 0 | 0 | 0 | |
| Interest | 14 | 15 | 17 |
| Depreciation | 15 | 17 | 18 |
| Profit before tax | -11 | 5 | -34 |
| Tax % | -18% | -41% | |
| -9 | 7 | -31 | |
| EPS in Rs | -5.73 | 4.25 | -19.54 |
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -31% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -404% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -19% |
| 5 Years: | -22% |
| 3 Years: | -34% |
| 1 Year: | -62% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 5% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|
| Equity Capital | 16 | 16 | 16 |
| Reserves | 120 | 133 | 112 |
| 107 | 96 | 95 | |
| 91 | 121 | 94 | |
| Total Liabilities | 334 | 366 | 317 |
| 148 | 163 | 159 | |
| CWIP | 8 | 3 | 4 |
| Investments | 0 | 0 | 0 |
| 178 | 201 | 155 | |
| Total Assets | 334 | 366 | 317 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| 4 | 43 | |
| -12 | -19 | |
| 5 | -22 | |
| Net Cash Flow | -3 | 1 |
| Free Cash Flow | -8 | 23 |
| CFO/OP | 23% | 118% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2024 | Mar 2025 | |
|---|---|---|
| Debtor Days | 28 | 45 |
| Inventory Days | 185 | 303 |
| Days Payable | 99 | 199 |
| Cash Conversion Cycle | 113 | 149 |
| Working Capital Days | 11 | 5 |
| ROCE % | 8% |
Insights
In beta| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & Development Spend INR Lakhs ・Standalone data |
|
|||||||||||
| Sale of Products (API/Intermediates) INR Lakhs ・Standalone data |
||||||||||||
| Total Number of Employees Count ・Standalone data |
||||||||||||
| Export Turnover INR Lakhs ・Standalone data |
||||||||||||
| Number of WHO Approved DMFs Count ・Standalone data |
||||||||||||
| Number of Research Scientists Count ・Standalone data |
||||||||||||
| Manufacturing Capacity - APIs TPA ・Standalone data |
||||||||||||
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Change in Management
26 Mar - Company Secretary Anuradha Pandey resigns effective 29 Mar 2026; Shweta Patel appointed effective 1 Apr 2026.
-
Board Meeting Outcome for Outcome Of Board Meeting For Resignation Tendered By CS Anuradha Pandey Accepted By The Board, Approval For The Appointment Of New Company Secretary Nominated By NRC, Ms. Shweta Patel.
26 Mar - Company Secretary Anuradha Pandey resigns effective 29 Mar 2026; Shweta Patel appointed effective 1 Apr 2026.
-
Board Meeting Intimation for Board Meeting Intimation To Be Held On 26Th March, 2026
24 Mar - CS Anuradha Pandey resigns effective 29 Mar 2026; Shweta Patel appointed CS effective 1 Apr 2026.
- Closure of Trading Window 24 Mar
-
Defaults under Para A sub-paragraph 6 of Schedule III-Subsequent Disclosure
18 Mar - Defaulted on Bank of Maharashtra Rs.979.21L (from 17/10/2025) and Bank of Baroda Rs.606.08L (from 20/10/2025).
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2013
from nse
-
Financial Year 2012
from nse
Business Overview:[1]
Company manufactures bulk drugs, organic and inorganic chemicals. It is among the few companies which are World Health Organization -approved Indian companies to be associated with the William J Clinton Foundation for manufacture of anti-malarial drugs. Company supplies artemisinin-based bulk drugs to pharmaceutical companies, for manufacturing anti-malarial formulations